Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

114.34
-1.3600-1.18%
Volume:298.79K
Turnover:34.48M
Market Cap:12.36B
PE:252.04
High:116.97
Open:114.42
Low:113.20
Close:115.70
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.43
T/O Rate:0.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.51
PE(LYR):139.44

Loading ...

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 28

U.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler

Reuters
·
May 28

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $135 From $110

THOMSON REUTERS
·
May 28

Corcept Therapeutics to resubmit NDA to U.S. FDA for relacorilant

TIPRANKS
·
May 27

BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients

Reuters
·
May 27

Corcept plans to resubmit FDA NDA for relacorilant in Cushing’s syndrome after CRL

Reuters
·
May 27

Corcept Therapeutics Inc - FDA Expects Pdufa Date Six Months After Nda Resubmission for Relacorilant

THOMSON REUTERS
·
May 27

Corcept to Resubmit Its New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
May 27

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

Simply Wall St.
·
May 18

Corcept Therapeutics Shares Rise After UBS Upgrade

MT Newswires Live
·
May 14

Corcept Therapeutics Inc : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
May 13

Corcept Therapeutics upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 13

Corcept Therapeutics Raised to Buy From Neutral by UBS

Dow Jones
·
May 13

UBS Upgrades Corcept Therapeutics to Buy From Neutral, Adjusts Price Target to $72 From $44

MT Newswires Live
·
May 13

Corcept CEO Joseph Belanoff disposes 40,000 shares worth $2 million

Reuters
·
May 06

Corcept Therapeutics Signals Big Growth After Key Wins

TIPRANKS
·
May 05

Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
May 04

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 04

Corcept Therapeutics price target raised to $75 from $60 at H.C. Wainwright

TIPRANKS
·
May 04

Corcept Therapeutics Inc. : H.c. Wainwright Raises Target Price to $75 From $60

THOMSON REUTERS
·
May 04